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Objectives. This study sought to examine the hemodynamic and
autonomic dose response to digoxin.
Background. Previous studies have demonstrated an increase
in contractility and heart rate variability with digitalis prepara-
tions. However, little is known about the dose-response to digoxin,
which has a narrow therapeutic window.
Methods. Nineteen patients with moderate heart failure and a
left ventricular ejection fraction <0.45 were studied hemodynam-
ically using echocardiography and blood pressure at baseline and
after 2 weeks of low dose (0.125 mg daily) and 2 weeks of moderate
dose digoxin (0.25 mg daily). Loading conditions were altered with
nitroprusside at each study. Autonomic function was studied by
assessing heart rate variability on 24-h Holter monitoring and
plasma norepinephrine levels during supine rest.
Results. Low dose digoxin provided a significant increase in
ventricular performance, but no further increase was seen with
the moderate dose. Low dose digoxin reduced heart rate and
increased heart rate variability. Moderate dose digoxin produced
no additional increase in heart rate variability or reduction in
sympathetic activity, as manifested by heart rate, plasma norepi-
nephrine or low frequency/high frequency power ratio. In addi-
tion, we did not find that either low or moderate dose digoxin
increased parasympathetic activity.
Conclusions. We conclude that moderate dose digoxin provides
no additional hemodynamic or autonomic benefit for patients with
mild to moderate heart failure over low dose digoxin. Because
higher doses of digoxin may predispose to arrhythmogenesis,
lower dose digoxin should be considered in patients with mild to
moderate heart failure.
(J Am Coll Cardiol 1997;29:1206–13)
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In the 200 years since Sir William Withering popularized the
use of digitalis preparations (1), we have only relatively
recently elucidated many of its beneficial effects in patients
with heart failure. Both hemodynamic (2–4) and functional
(5–8) improvement have been achieved with digitalis, due in
part to improved contractility (2) and relaxation (2) in the
heart with systolic dysfunction. In addition, digoxin may reduce
systemic sympathetic activity by a direct effect on barorecep-
tors (9–11). Despite these beneficial effects, digitalis has a
neutral effect on mortality as demonstrated by the recently
completed Digitalis Investigation Group (DIG) trial (12).
However, the DIG trial suggested a trend toward a beneficial
effect of digitalis on pump failure death but an adverse effect
(although not statistically significant) on death due to other
cardiovascular causes (including sudden death). These findings
may be consistent with a narrow therapeutic range for digoxin,
especially in patients who have reduced renal perfusion due to
poor stroke volume (13–15). Such patients may easily become
toxic from digoxin and suffer arrhythmias and sudden death.
Little data exist on the dose response of digitalis prepara-
tions. Several previous studies have suggested improved left
ventricular function with higher doses of digitalis (16–24), and
one study suggests no additional benefit of higher dose digoxin
(25). However, these studies only examined systolic time
intervals or ejection fraction, which are load- and heart-rate
dependent indexes of left ventricular performance. Thus,
alterations in load, such as a reduction in afterload, may
account for such findings. Although digoxin reduces sympa-
thetic activation (9–11,26) and increases parasympathetic ac-
tivity (26), little data exist on the autonomic dose-response of
digoxin. Because digoxin may have arrhythmic effects at higher
doses, it is important to understand whether higher doses of
digoxin result in hemodynamic or autonomic benefit. For this
reason, we examined the hemodynamic and autonomic dose
response to digoxin. Our hypothesis was that digoxin would
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provide a dose-dependent increase in left ventricular perfor-
mance, a reduction in sympathetic activity and an increase in
parasympathetic activity.
Methods
Patient selection. Nineteen men (mean [6SD] age 64 6 12
years), all with normal sinus rhythm, were enrolled in the
study. On the basis of clinical findings, 13 patients were in New
York Heart Association functional class II, and 6 were in
functional class III. The etiology of heart failure was coronary
artery disease in 11 patients, presumed alcoholic cardiomyop-
athy in 4, hypertension in 1, valvular heart disease in 1 and
idiopathic in 2. The four patients with presumed alcoholic
cardiomyopathy were no longer actively drinking. Mean left
ventricular ejection fraction as measured by multiple gated
acquisition before study entry was 0.28 6 0.09 (range 0.14 to
0.43). Fifteen patients completed both the echocardiographic
and Holter portions of the trial. Echocardiography was tech-
nically difficult in three patients, and only Holter data were
collected. One patient had excessive ventricular ectopic beats,
and only echocardiographic data were collected.
All but one patient were receiving a constant dose of
angiotensin-converting enzyme inhibitor throughout the study
(captopril in nine, ramapril in four, benazepril in three,
enalapril in two). The one patient not receiving an angiotensin-
converting enzyme inhibitor was taking hydralazine and isosor-
bide dinitrate. Seventeen patients received diuretic drugs
throughout the study, and the dose of these drugs did not
change. No patient had received digoxin for at least 3 months
before study entry. Five patients were receiving isosorbide
dinitrate, two were receiving amlodipine, one was receiving
diltiazem, two were receiving metoprolol, and one was receiv-
ing amiodarone. No patient was taking a sympathomimetic
agent, such as a bronchodilator. Apart from digoxin, no
medication changed during the study period in any patient. No
patient had a myocardial infarction within the previous 3
months. All patients had a creatinine level ,2.0 mg. One
patient had diabetes mellitus and was excluded from the
Holter analysis to avoid any possible confounding problem
with diabetic autonomic dysfunction.
Study protocol. The study was approved by the Institu-
tional Review Board for Ethical Treatment of Patients at the
Dallas Veterans Affairs Medical Center, Dallas, Texas. Fur-
thermore, all patients gave written informed consent before
the study.
At baseline, patients had serum digoxin and plasma norepi-
nephrine levels measured after 30 min of supine rest. During
the same visit, the baseline echocardiographic assessment of
the left ventricular stress-shortening relation was performed
(27). Briefly, echocardiographic images were collected in the
standardized short- and long-axis views before and after small
doses of intravenous nitroprusside were infused to lower
systolic blood pressure. Left ventricular dimensions, fractional
shortening and wall stress were measured by echocardiography
at three levels of afterload. Twenty-four hour Holter monitor-
ing was then performed for measurement of heart rate vari-
ability (HRV). The patients were then treated with 0.125 mg/day
of oral digoxin for 2 weeks.
After 2 weeks of 0.125 mg of digoxin (and then 2 weeks of
0.25 mg), the patients returned for repeat measurement of
serum digoxin and plasma norepinephrine levels. Repeat mea-
surements of wall stress and fractional shortening were ob-
tained in a similar manner, as previously described. In addi-
tion, 24-h Holter monitoring was again performed to measure
HRV variables. Because digoxin has a narrow therapeutic
window, doses higher than 0.25 mg/day were not used so as to
maintain patient safety.
Echocardiographic data. All subjects underwent two-
dimensional echocardiography in the left lateral decubitus
position using a Vingmed CFM750 instrument with a 3.25-
MHz transducer (Vingmed Sound, Horten, Norway). Paraster-
nal long-axis and midventricular parasternal short-axis images
were acquired and recorded on 0.5-in. VHS videotape for
subsequent analysis. Repeat images were obtained before each
incremental increase in the infusion rate of nitroprusside and
were also recorded on 0.5-in. VHS videotape. Patients under-
went continuous electrocardiographic monitoring, and blood
pressure was recorded at 1-min intervals using an automated
cuff.
The left ventricular stress-shortening relation was measured
using methodology previously published from our laboratory
(28). All echocardiographic images were interpreted by an
observer (P.A.G.) who had no knowledge of the patient’s
digoxin dose. Fractional shortening (FS) was measured in the
parasternal long-axis view using the following formula:
FS% 5 LVIDd 2 LVIDs/LVIDd 3 100,
where LVIDd 5 left ventricular internal diameter at end-
diastole; and LVIDs 5 left ventricular internal diameter at
end-contraction. Fractional shortening was normalized for
heart rate by dividing fractional shortening by the square root
of the RR interval to yield the heart rate-corrected fractional
shortening. This was done to help eliminate the confounding
factor of heart rate effects.
Meridional wall stress (MWS) was calculated using the
following formula:
MWS 5 P~LVIDs!/4h ~1 1 h/LVIDs!,
where P 5 systolic (cuff) blood pressure; LVIDs 5 left
ventricular end-systolic dimension; and h 5 posterior wall
thickness (29).
Abbreviations and Acronyms
HRV 5 heart rate variability
NN.50 5 number of successive beats differing by .50 ms
RMS-SD 5 root mean square of RR interval
SDANN 5 standard deviation of average normal RR
intervals for successive 5-min segments
SDNN 5 standard deviation of RR interval
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Measurement of HRV. All Holter recordings were made
on a 8500 model Marquette recorder and were analyzed in
blinded manner by an experienced Holter technician using a
DelMar 363 scanner. DelMar installed a selectable acquisition
formation for Marquette recorders on the Delmar scanner to
ensure accuracy of analysis of the Marquette recordings on the
Delmar scanner. The heart period variability spectrum was
computed using fast Fourier transformation, as described fully
elsewhere (30,31).
Determinations of frequency domain included measure-
ments of low and high frequency power. Low frequency power
(0.05 to 0.15 Hz) has been shown to be a marker of sympathetic
and parasympathetic HRV; furthermore, high frequency
power (0.15 to 0.35 Hz) was used as a marker of parasympa-
thetic modulation of heart rate (32–35).
Time domain variables obtained included the standard
deviation of the RR interval (SDNN), root mean square of the
RR interval (RMS-SD) and the number of successive beats
differing by .50 ms (NN.50). SDNN has been shown to be
closely correlated with total power of HRV and has been
shown to be a predictor of mortality after myocardial infarction
(36,37). In addition, both RMS-SD and NN.50 have been
shown (38) to be highly correlated with high frequency power
and can be used as a marker of parasympathetic activity (38).
Measurement of plasma norepinephrine. After a 21-gauge
intravenous catheter was inserted, patients were placed in the
supine position for 30 min. Blood was then collected in a
heparinized tube and placed immediately on ice. Within
15 min, the blood was centrifuged at 4°C for 15 min at 1,000 6
100g. The plasma was then frozen at 270°C until it could be
sent for analysis. Analysis was performed by Smith, Kline,
Bio-Science Laboratories using high pressure liquid chroma-
tography with electrochemical detection.
Statistical analysis. Repeated measures analysis of vari-
ance was used to determine the effects of increasing doses of
digoxin on HRV and hemodynamic variables. Significant dif-
ferences among the digoxin dose levels were tested using
Scheffe´ multiple comparisons. The natural logarithm of high
and low frequency power was used in the statistical analysis
because these variables were positively skewed. A p value
,0.05 was considered statistically significant, and descriptive
statistics are provided as mean value 6 SD.
A two-factor (digoxin dose and nitroprusside dose) re-
peated measures analysis of covariance was used to examine
the effect of load as a covariate and digoxin dose on fractional
shortening (using a stress-shortening relation). This analysis
was performed using both fractional shortening with and
without the correction for heart rate as dependent variables to
eliminate the confounding factor of heart rate effects. Individ-
ual differences in stress shortening between baseline and low
dose and moderate dose digoxin were examined by the Scheffe´
F test. Least squares mean estimates 6SD of fractional
shortening for each digoxin dose level are presented and are
compared using Bonferroni-adjusted t tests, that is, using p ,
0.017 (0.05 divided by 3, for the number of comparisons made)
to indicate statistical significance. These least squares mean
values provide estimates of mean fractional shortening for each
digoxin dose level at an average level of load; the digoxin dose
level comparisons are statistically adjusted for the effect of load.
Results
Hemodynamic dose-response. Fifteen of the 19 patients
studied had complete or technically satisfactory echocardio-
graphic studies. The hemodynamic and echocardiographic
dose-responses to digoxin in these patients are shown in Table
1. Serum digoxin levels increased from undetectable at base-
line to 0.8 6 0.5 at low dose digoxin (p , 0.0001 vs. baseline)
to 1.5 6 0.7 at moderate dose digoxin (p , 0.0001 vs. baseline;
p 5 0.0001 vs. low dose). At echocardiographic study, heart
rate had decreased nonsignificantly, from 81 6 13 to 70 6 18
beats/min at low dose digoxin (p 5 0.064), with no further
decrease after moderate dose digoxin. Systolic blood pressure
by cuff increased nonsignificantly from 126 6 16 to 137 6
22 mm Hg after low dose digoxin (p 5 0.088), with no further
increase after moderate dose digoxin. There were no signifi-
cant changes in rest left ventricular end-diastolic dimensions
with either low or moderate dose digoxin. However, end-
systolic dimensions (uncorrected for afterload) decreased from
5.1 6 0.8 to 4.9 6 0.7 cm at low dose digoxin to 4.7 6 0.9 cm
Table 1. Hemodynamic/Echocardiographic Dose-Response of Digoxin
Baseline
(mean 6 SD)
Low
Dose Digoxin
(mean 6 SD)
Moderate
Dose Digoxin
(mean 6 SD)
p Value
(ANOVA)
Digoxin level (ng/ml) 0.0 6 0.0 0.8 6 0.5* 1.5 6 0.7*† ,0.0001
HR (beats/min) 81 6 13 70 6 18 72 6 15 0.064
Systolic blood pressure (mm Hg) 126 6 16 137 6 22 134 6 22 0.088
LV end-diastolic dimension (cm) 5.6 6 0.8 5.6 6 0.6 5.3 6 0.8 0.111
LV end-systolic dimension (cm) 5.1 6 0.8 4.9 6 0.7 4.7 6 0.9* 0.049
Fractional shortening (%) 9.1 6 5.3 12.9 6 6.9 12.5 6 6.6 0.123
Fractional shortening
(HR corrected)
0.33 6 0.18 0.43 6 0.22 0.42 6 0.22 0.22
*p , 0.05 versus baseline by Scheffe´ F test. †p , 0.05 versus low dose digoxin by Scheffe´ F test. ANOVA 5 analysis
of variance; HR 5 heart rate; LV 5 left ventricular.
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at moderate dose digoxin (p 5 0.049 for moderate dose vs.
baseline). Fractional shortening (uncorrected for load) did not
change significantly at low dose (from 9.1 6 5.3% to 12.9 6
6.9%) or at moderate dose (12.5 6 6.6%) digoxin.
Figure 1 demonstrates the dose-response of the left ven-
tricular stress–shortening relation with and without correction
for heart rate. Analysis of covariance showed a significant
interaction with digitalis with regard to fractional shortening as
a function of its covariate, end-systolic wall stress (p 5 0.003)
and with regard to heart rate-corrected fractional shortening as
a function of the same covariate, end-systolic wall stress (p 5
0.0035). There was a significant upward shift of this relation
with low dose digitalis compared with baseline (p 5 0.002 for
fractional shortening vs. end-systolic wall stress; p 5 0.017 for
heart rate-corrected fractional shortening vs. end-systolic wall
stress). Moderate dose digoxin produced no further increase in
performance compared with low dose digoxin, as shown in
Figure 1 (p 5 0.88 for fractional shortening vs. end-systolic
wall stress at moderate vs. low dose; p 5 0.98 for heart
rate-corrected fractional shortening vs. end-systolic wall stress
at moderate vs. low dose). These data suggest an improvement
in performance with low dose digoxin and no further improve-
ment with moderate dose digoxin.
Results of the least-squares mean estimates of mean frac-
tional shortening for each digoxin dose level at an average level
of load are shown in Table 2. A significant increase in
fractional shortening (p 5 0.0059) and a nearly significant
increase in heart rate-corrected fractional shortening (p 5
0.029) are present with low dose digoxin, with no further
change after moderate dose digoxin.
Autonomic dose-response. The heart rate variability dose-
responses to digoxin are shown in Table 3. Low dose digoxin
significantly lowered average heart rate (p 5 0.006) recorded
over 24 h, from 87 6 10 to 82 6 10 beats/min, with no further
change on moderate dose digoxin (p 5 NS for moderate vs.
low dose).
In the time domain analysis, low dose digoxin increased
HRV, as reflected by SDNN (p 5 0.028) and the standard
deviation of the averages of NN intervals in all 5-min segments
of the entire recording (SDANN) (p 5 0.012), with no further
increase after moderate dose digoxin. Digoxin at both low and
moderate doses did not produce a change in RMS-SD or
NN.50 (surrogate measures of parasympathetic activity).
In the spectral analysis, low dose digoxin did not increase
high frequency power (parasympathetic) (5.8 6 1.5 to 6.1 6
1.4). There was no difference in moderate versus low dose
digoxin in the high frequency range. In the low frequency
spectrum, which reflects both sympathetic and parasympa-
thetic activity, low dose digoxin produced a trend toward an
increase in power (p , 0.1 low dose vs. baseline) that did not
increase further with moderate dose digoxin. The ratio of low
frequency to high frequency power and plasma norepineph-
Table 2. Least-Squares Mean Estimates of Fractional Shortening for
Each Digoxin Dose at Average Level of Load
Digoxin
Dose
Least-Squares
Mean Estimate SD
p Value
vs. Baseline vs. Low Dose
FS (%)
Baseline 10.6 7.1 — 0.0059
Low dose 14.6 7.2 0.0059 —
Moderate dose 13.7 6.5 0.027 0.526
FSc
Baseline 0.40 0.25 — 0.029
Low dose 0.51 0.25 0.029 —
Moderate dose 0.49 0.23 0.06 0.73
FS 5 fractional shortening; FSc 5 heart rate corrected fractional shortening.
Figure 1. Fractional shortening (FS) (top) and heart rate-corrected
fractional shortening (FSc) (bottom) are plotted against their covari-
ate, end-systolic wall stress for baseline (BSLN) and low (LD) and
moderate dose (MD) digoxin. Analysis of covariance demonstrated a
significant effect of digoxin on these relations (p 5 0.003 for fractional
shortening, p 5 0.0035 for heart rate-corrected fractional shortening).
The Scheffe´ F test revealed an upward shift of this relation with low
dose digoxin (p 5 0.012 for fractional shortening, p 5 0.034 for heart
rate-corrected fractional shortening), with no additional effect with
moderate dose digoxin.
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rine, surrogate measures of sympathetic autonomic activity,
did not change with either low or moderate dose digoxin.
Discussion
The results of the present study demonstrate both a hemo-
dynamic and an autonomic benefit of digoxin at low dose
(0.125 mg daily), with no clinically significant additional benefit
at moderate dose (0.25 mg daily). To our knowledge, this is the
first long-term study to examine the dose-response of digoxin
using a relatively load-independent index of performance.
Additionally, we believe that this is the first study to examine
the dose-response of digoxin on autonomic activity.
Dose-ranging hemodynamic results. Several previous in-
vestigators have found a hemodynamic dose-response to
digoxin (16–24) whereas others have not (25). However,
several of these studies were short-term intravenous studies
(16–19,21,22) with uncertainty regarding the steady state ki-
netics of the drug and measured glycoside levels transiently in
the toxic range. In addition, ventricular function was measured
by systolic time intervals (16–20,23) or ejection fraction
(24,25), which are load- and heart rate-dependent measure-
ments. In addition, the study by Gheorghiade et al. (24) did not
examine patients before digoxin administration to assess
whether a majority of its beneficial effects occurred at low
dose. To eliminate these limitations, we studied the dose-
response to digoxin before any administration of drug, at low
and moderate doses. We chose not to administer high dose
digoxin for patient safety. We also chose to use a relatively
load-independent index of ventricular function, a stress–
shortening relation before and after correction for heart rate
changes.
In contrast to Gheorghiade et al. (21), but like Ware et al.
(25), we did not find additional hemodynamic benefit of
digoxin at higher dosages. There are several reasons for the
differences between our study and that of Gheorghiade et al.:
1) The patients from the Gheorghiade et al. study were studied
after 12 weeks of therapy compared with our 2 weeks. Al-
though digoxin should be at an equilibrium state by 2 weeks,
long-term beneficial changes due to remodeling could have
taken longer to evolve, resulting in some improvement in
ejection fraction. 2) Measurement of ejection fraction by
radionuclide methods may have been more sensitive than our
use of fractional shortening by echocardiography, especially
because it encompasses global performance changes as op-
posed to a more regional view with echocardiography. In
contrast, ejection fraction does not take load or heart rate into
account, factors that may alter the result. Our assessment is
relatively independent of both heart rate and afterload. 3) It is
unlikely that differences in digoxin dosing can account for the
discrepancy because serum levels in the two studies were
comparable. In addition, it is doubtful that differences in
patient cohorts or background therapy could account for the
different findings of the two studies because the patient
demographics (including age) and background medications
were similar in the two trials.
It is unclear why left ventricular performance does not
increase more at moderate digoxin dosages. The lack of further
increase in performance is not a function of heart rate or
afterload alterations because these factors are accounted for by
our analysis. In addition, the lack of reduction in left ventric-
ular end-diastolic dimension suggests that preload is not
significantly changed. Thus, other factors must account for this
phenomenon. Although other investigators (26) have found an
increase in parasympathetic activity with digoxin, we did not.
Thus, we cannot account for the lack of incremental improve-
ment in left ventricular performance with moderate dose
digoxin by augmented parasympathetic activity. Further eval-
uation of this phenomenon, perhaps by examining the effect of
digoxin on neurohormones that may affect contractility (e.g.,
angiotensin II, endothelin-1, cytokines) and on biologic func-
tion of the myocytes (39), is warranted.
Dose-ranging autonomic results. Both the reduction in
heart rate and the increase in SDNN and SDANN at low dose,
with no further changes at moderate dose, suggest that the
majority of benefit of increasing heart rate variability is at low
dose.
We found a much more modest change in parasympathetic
activity than did Krum et al. (26). High frequency power did
not increase significantly with low dose digoxin (p 5 0.27). In
addition, RMS-SD and NN.50 did not change. These data
suggest that parasympathetic activity did not change signifi-
cantly in our patients. The finding that moderate dose digoxin
did not further increase high frequency power over low dose
digoxin suggests that increasing the dose of digoxin will not
produce further augmentation of parasympathetic activity. The
increase in low frequency power (p 5 0.074 for low dose vs.
baseline), an index of baroreflex activity, was consistent with
Table 3. Autonomic Dose Response to Digoxin (mean 6 SD)
Baseline
Low Dose
Digoxin
Moderate
Dose
Digoxin
p Value
(ANOVA)
Time Domain Analysis of HRV
HR (beats/min) 87 6 10 82 6 10* 81 6 12*† 0.006
SDNN (ms) 88 6 32 106 6 37* 103 6 42† 0.028
SDANN (ms) 77 6 30 95 6 32* 93 6 40*† 0.012
RMS-SD 29.4 6 16.7 32.1 6 16.3 29.1 6 8.7† 0.57
lnNN.50 8.4 6 1.0 8.6 6 0.7 8.4 6 0.7† 0.56
Spectral Analysis of HRV
lnHFP 5.8 6 1.5 6.1 6 1.4 6.1 6 1.2† 0.27
lnLFP 5.9 6 1.7 6.3 6 1.3 6.4 6 1.4† 0.074
LFP/HFP 1.2 6 0.4 1.3 6 0.6 2.0 6 2.6† 0.33
PNE (ng/ml) 347 6 148 362 6 177 362 6 178† 0.89
*p , 0.05 versus baseline by Scheffe´ F test. †p 5 NS versus low dose by
Scheffe´ F test. HFP 5 high frequency power; HRV 5 heart rate variability;
LFP 5 low frequency power; NN.50 5 number of pairs of adjacent NN
intervals differing by .50 ms in entire recording; PNE 5 plasma norepinephrine;
RMS-SD 5 square root of mean of sum of squares of differences between
adjacent NN intervals; SDANN 5 standard deviation of averages of NN intervals
in all 5-min segments of entire recording; SDNN 5 standard deviation of all NN
intervals; other abbreviations as in Table 1.
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the previous study of Krum et al. (26). However, there was no
additional benefit of moderate dose over low dose digoxin in
our study.
Sympathetic activity, as reflected by both the ratio of low to
high frequency power and by plasma norepinephrine did not
change at low or moderate dose digoxin. The study by Krum et
al. (26) demonstrated a reduction in plasma norepinephrine
from 552 6 80 to 390 6 37 ng/ml without any change in the
ratio of low to high frequency power. Another clinical trial (10)
found that digoxin resulted in a median reduction in plasma
norepinephrine of 98 from 339 pg/ml at baseline. The differ-
ences between our study and that of previous investigators is
unclear but is probably not due to differences in baseline
neurohormonal activation. Our baseline plasma norepineph-
rine level of 369 6 174 ng/ml is in between the baseline levels
found in these comparison trials (10,25). In addition, the
patients in the study by Krum et al. were younger, included
women and did not include patients taking other agents, such
as beta-adrenergic blocking agents and calcium antagonists,
and this may have accounted for some difference.
Clinical implications. The use of inotropic medications to
treat congestive heart failure has generally resulted in an
increase in mortality (40,41) despite their beneficial effects on
hemodynamic variables and functionality (8,42,43). This in-
crease in mortality seems to be due to an increase in sudden
death in some cases (44).
Digoxin appears to be a unique inotropic agent because it
has no adverse effect on mortality (12), which may be due to a
balance between beneficial neurohormonal (9–11,26) and
toxic arrhythmogenic effects (13–15). Our study has shown that
most of the beneficial effects occur at low dose, with little
additional hemodynamic or autonomic benefit at higher dose.
However, higher dose digoxin may predispose to toxic rhythm
problems, especially in older patients who are more likely to
have impaired renal function and therefore are likely to be
more prone to heightened digitalis levels and digitalis toxicity
(45,46). The subgroup analysis of the DIG study examining
digoxin levels and risk of sudden death should help to deter-
mine whether higher doses of digoxin provide little additional
benefit but higher risk of death.
Study limitations. The present study did not address the
use of higher dose digoxin to treat patients in atrial fibrillation.
In such patients, digoxin may have the additional benefit of
rate control. In addition, because patients in functional class
IV were not studied, we can make no conclusions about the
dose-response effects of digoxin in the sickest patients. Be-
cause patients in functional class IV may have the greatest
degree of dysautonomia, higher doses of digoxin may be more
efficacious in these patients, although this efficacy has yet to be
proved.
Although this was not a double-blind, placebo-controlled
trial, assessment of Holter monitoring and echocardiograms
was performed by independent observers, in blinded manner,
who were unaware of the dose of digoxin for each patient or
the time of assessment. Because the hypothesis of the study
was not to show digoxin efficacy, which has been previously
demonstrated (6–8), each patient was his own control.
The use of fractional shortening as opposed to a more
global assessment of shortening may be less sensitive to smaller
or more regional changes in shortening. However, this may be
a special problem in assessing patients with coronary artery
disease. This methodology has been used in previous studies in
humans with good reproducibility (27,28). Despite the fact that
we did not use a more global assessment of shortening, we
were able to detect changes in performance between baseline
and low dose digoxin using this technique. If there were any
undetected additional changes in shortening between low and
moderate dose digoxin, these changes were probably not
clinically significant.
The use of a cuff systolic blood pressure instead of end-
systolic pressure to determine systolic wall stress is less accu-
rate than using intraventricular pressure. However, because
this was a noninvasive study, the use of cuff blood pressure was
more practical. In addition, we have examined the relation of
invasively determined end-systolic and peak systolic pressure
in 25 patients with heart failure and found a close correlation
(peak systolic pressure 19.46 mm Hg, end-systolic pressure
1.349 mm Hg, r2 5 0.86, p , 0.0001) (unpublished data).
The Holter monitor studies were performed after the
echocardiographic study. Because nitroprusside increases sino-
aortic baroreflex activation, we waited at least 10 to 15 min
after the echocardiographic studies to place the Holter moni-
tors. In all patients, blood pressure and heart rate had returned
to baseline values when the Holter monitors were placed.
Moreover, because the baseline, low dose and moderate dose
digoxin studies were all performed in an identical manner, any
changes over time would reflect the digoxin effect and not the
nitroprusside effect. In addition, plasma norepinephrine was
drawn before echocardiographic study and was thus indepen-
dent of any nitroprusside effect.
Although many of our patients were taking other medica-
tions that could affect the autonomic nervous system, such as
angiotensin-converting enzyme inhibitors, diuretic drugs and
beta-blockers for background therapy, the patients were all in
stable condition during this background treatment for at least
3 months before study entry, and no change in medication
(other than digoxin) was made during the study period. Thus,
although these medications can alter the adrenergic nervous
system, the addition of digoxin to this stable background
therapy provides a “real-world” test of the effects of digoxin.
However, a repeat study with no other background therapy is
warranted.
Five patients had underlying conditions that could impair
baroreflex mechanisms. One patient had diabetes and was
excluded from Holter analysis, and four had some history of
hypertension but were included in the analysis. When the
diabetic patient was added to the analysis, or the four patients
with hypertension were excluded, the Holter results were
unchanged.
The results of the present study reflect a 2-week treatment
period with each dose of digoxin. We cannot exclude the
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possibility that longer term effects of digoxin on remodeling,
left ventricular function and the autonomic nervous system
would have been present had we studied these patients after
several months of therapy. However, the findings of a hemo-
dynamic and autonomic benefit at 2 weeks of therapy suggests
that benefit can be detected early. In addition, previous studies
(9) in humans have shown that baroreflex mechanisms may be
reset within minutes with a rapid acting digitalis. If any bias
existed in the present study due to late effects, it was toward
moderate dose digoxin because this measurement was made
after an additional 2 weeks of digoxin therapy. In addition,
large amounts of remodeling have not been reported as a
consequence of digoxin therapy. Thus, this was probably of
minimal importance.
Conclusions. The results of this study suggest that moder-
ate dosages of digoxin may not have a significant hemodynamic
or autonomic advantage over low dose digoxin in patients with
moderate heart failure in normal sinus rhythm. Because
digoxin has a narrow therapeutic index and higher dosages may
predispose to arrhythmias, the use of low dose digoxin may be
preferable. This is especially true because patients with heart
failure often have fluctuating renal perfusion and thereby have
altered kidney function, which may predispose to toxicity.
We acknowledge the technical assistance of Arvella Peters, University of Texas
Southwestern and Dallas Veterans Affairs Medical Center, Dallas, Texas.
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